The present invention relates to large scale manufacture of nanoscale microsheets for use in applications such as wound healing or modification of a biological or medical surface.

The invention relates to an adhesive transdermal therapeutic system containing, as an active principle, an association of valentonin (VLT) and 6-methoxyharmalan (6-MH).

A benefit agent delivery system can deliver benefit agents on demand. The benefit agent delivery system comprises a first electrode layer, a microcell layer comprising a plurality of microcells, and a porous second electrode layer. Each of the plurality of microcells are filled with a liquid mixture comprising reverse micelles in a hydrophobic liquid that are formed from a polar liquid, a surfactant or stabilizing particles, and a benefit agent. Application of an electric field across a microcell layer causes an increase in the rate of release of the benefit agent of the microcell through the porous second electrode layer.

A method for creating a consolidated compound for delivering an immunomodulatory and imiquimod to a patient, comprising diluting immunomodulator extract to a desired dilution by transferring a desired quantity of the concentrated immunomodulator to an associated sterile container, the associated sterile container having a defined volume of diluted immunomodulator after dilution thereof, providing a viscous encapsulation material, selecting a prescribed amount of concentrated immunomodulator, the prescribed amount defined as that amount of the diluted immunomodulator extract required to provide a number of doses equal to the number of dispensable increments from the container containing the viscous encapsulation material, introducing the selected amount of each of the diluted immunomodulator extract into the viscous encapsulation material, introducing an amount of imiquimod into the viscous encapsulation material, and mixing the introduced amount of each of the diluted immunomodulator extracts and the introduced amount of imiquimod with the viscous encapsulating material.

Molecular hydrogen has been shown to have cosmetic and medicinal benefits. However, delivery methods have been ineffective in aiding the body in receiving and absorbing the hydrogen. This device has a dry chemical separated from a solution. Both the dry chemical and the solution are housed in a container. The container has a hydrogen impermeable top outer layer and a hydrogen permeable bottom layer. Once initiated, a determined and controlled chemical reaction generates molecular hydrogen within the container. The hydrogen then exits the device through the hydrogen permeable side of the device that is facing the skin. The device carries a low risk of toxicity while providing cosmetic and medicinal advantages.

The present disclosure provides a transdermal delivery systems for delivering donepezil free base to patients suffering from central nervous system disorders including dementia and Alzheimer's. The transdermal delivery systems can have a separating layer having at least one surface with a surface energy of at least 40 Dynes, sodium bicarbonate particles in the drug matrix layer where the sodium bicarbonate particles have a D90 particle size of from 0.1 μm to 1000 μm, or a combination thereof.

The present invention relates to a method for producing a drug delivery system. The method comprises the steps of screen-printing a base paste, and curing the base paste. Furthermore, the method comprises the steps of screen-printing a first paste separate to the base paste, and curing the first paste.

A method for delivering a therapeutic agent to a subject from a transdermal delivery system is described, where the therapeutic agent (i) has a half-life in the blood when delivered orally of greater than about 48 hours and (ii) is for the treatment of a chronic condition. The transdermal delivery system achieves transdermal delivery of the therapeutic agent at steady state that is bioequivalent to administration of the therapeutic agent orally, wherein bioequivalency is established by (a) a 90% confidence interval of the relative mean Cmax and AUC of the therapeutic agent administered from the transdermal delivery system and via oral delivery between 0.70 and 1.43 or between 0.80 and 1.25, or (b) a 90% confidence interval of the ratios for AUC and Cmax of the therapeutic agent administered from the transdermal delivery system and via oral delivery between 0.70 and 1.43 or between 0.80 and 1.25.

The present invention relates to a method for producing a drug delivery system. The method comprises the steps of screen-printing a base paste, and curing the base paste. Furthermore, the method comprises the steps of screen-printing a first paste separate to the base paste, and curing the first paste.

The present disclosure provides a transdermal delivery system for treating Alzheimer’s disease with donepezil, optionally in combination with a second therapeutic agent such as aducanumab.